Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Curr Hematol Malig Rep. 2018 Oct;13(5):383–395. doi: 10.1007/s11899-018-0471-9

Table 1.

Tumor mutational load as predictive biomarker of response to checkpoint blockade

Checkpoint blockade
therapy		 Tumor
type		 Patients (n, discovery +
validation)		 Biopsy time point relative to
treatment		 Parameter associated with clinical
benefit		 Reference
Ipilimumab Melanoma 25 + 39 Baseline and on-treatment >100 non-synonymous coding mutations [7•]
Pembrolizumab NSCLC 16 + 15 Baseline (1 on-treatment) > 209 and 200 (median) non-synonymous mutations [8•]
Ipilimumab Melanoma 110 Baseline No cutoff [9]
Pembrolizumab and nivolumab Melanoma 38 Baseline (4 early on-treatment) > 600 non-synonymous mutations (in the top 3rd) [10]
Ipilimumab + nivolumab NSCLC 75 Baseline (1 on-treatment) >158 (median) non-synonymous + indel mutations [12]